INMB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
1.5M
-74.6%
5.8M
+6.2%
5.5M
-26.4%
7.4M
-69.7%
24.6M
R&D
-803000
-122.1%
3.6M
+56.3%
2.3M
-52.3%
4.9M
-15.8%
5.8M
SG&A
2.3M
+5.0%
2.2M
-31.0%
3.1M
+23.5%
2.5M
+13.0%
2.3M
Operating Income
-1476000
+74.6%
-5812000
-6.2%
-5474000
+26.4%
-7433000
+69.7%
-24571000
EBITDA
-1410000
+75.5%
-5760000
-6.3%
-5418000
+26.8%
-7405000
+8.1%
-8057000
Net Income
-1273000
+76.5%
-5407000
-2.7%
-5264000
+18.7%
-6472000
+73.5%
-24458000
EPS (Basic)
$-0.05
+75.0%
$-0.20
+0.0%
$-0.20
+16.7%
$-0.24
+77.1%
$-1.05
EPS (Diluted)
$-0.05
+75.0%
$-0.20
+0.0%
$-0.20
+16.7%
$-0.24
+77.1%
$-1.05
Shares (Diluted)
26.7M
+0.5%
26.6M
-0.2%
26.7M
+0.2%
26.6M
+14.1%
23.3M
INmune Bio (INMB) โ€” Financials